Aspire Biopharma Holdings, Inc.
ASBPNASDAQHealthcareBiotechnology
Latest quote
$7.92
−$0.0859 · -1.08%
ASBP company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
60
Fair Value
Momentum
56
Neutral
Sentiment
51
Mixed
Risk resilience
43
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Kraig T. Higginson
- Listed since
- Feb 20, 2025
- Employees
- 2
Market position
- Volume
- 39.27K
- 0.06× average
- Average volume
- 660.57K
- Average daily volume
- Market cap
- 909.6K USD
- Beta
- 0.15
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 237.18M USD
- P/E (TTM)
- -0.98×
- P/B (TTM)
- 0.7×
- P/S (TTM)
- 9.31×
- EV / EBITDA
- -20.93×
- Earnings yield
- -10.34%
- Free cash flow yield
- -2.08%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 18.35%
- Operating margin
- -7259.85%
- Net margin
- -11314.12%
- Return on equity
- 383.93%
- Return on assets
- -1865.68%
- Return on invested capital
- 395.26%
Financial health
- Debt / equity
- 0×
- Current ratio
- 0.17×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.2K USD | — | — | — | — |
| Cost of goods sold | 6.32K USD | — | — | — | — |
| Gross profit | −116 USD | — | — | — | — |
| Research and development | 923.91K USD | 144.36K USD | 72.05K USD | 175.32K USD | — |
| Selling, general, and administrative | 18.43M USD | 3.09M USD | 1.34M USD | 976.35K USD | 27.79K USD |
| Operating expenses | 19.35M USD | 3.09M USD | 1.34M USD | 976.35K USD | 25.48K USD |
| Interest income | — | 548.68K USD | 5.81M USD | 4.32M USD | — |
| Interest expense | 8.53M USD | −892K USD | 8.97K USD | — | — |
| Depreciation and amortization | 8.02M USD | — | 1.34M USD | — | 27.79K USD |
| Operating income | −19.35M USD | −3.09M USD | −1.34M USD | −976.35K USD | −25.48K USD |
| Net income | −24.48M USD | −12.54M USD | 4.46M USD | 3.34M USD | −25.48K USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- -1
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
ASBP peers
ETFs holding ASBP
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research ASBPresearch.disclaimer